Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Board OKs Safeguard to Protect Investors Against Abusive Tactics, Including Takeover

NEW YORK, July 14 (GenomeWeb News) - The board of directors of Alnylam Pharmaceuticals has approved a rights agreement to ensure that its stockholders receive preferred stock purchase rights in case of certain 'abusive tactics,' the Cambridge, Mass.-based RNAi company said today.


The amendment specifically states it will protect "the long-term value of the stockholders' investment" in the event of a takeover or other actions that could affect the ownership or leadership of the company, according to Alnylam.


"The board believes the rights agreement is a prudent measure to safeguard the interests of our stockholders so that they receive fair and equal treatment in the event of any proposed takeover of Alnylam and to guard against partial tender offers, squeeze-outs and other abusive tactics to gain control of Alnylam that could impair the board's ability to represent stockholders' interests fully," Alnylam president and CEO John Maraganore said in a statement.


More information about the rights agreement can be found here.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.